Tramadol hydrochloride is a Small Molecule owned by Grunenthal, and is involved in 13 clinical trials, which were completed.

Tramadol is a centrally acting synthetic opioid acts as mu-opioid Receptor agonist. It is a non-selective pure agonist at mu, delta, and kappa opioid receptors with a higher affinity at the mu receptors. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Other mechanisms that contribute to its analgesic effect are inhibition of neuronal re-uptake of noradrenaline as well as increased serotonin release.

The revenue for Tramadol hydrochloride is expected to reach a total of $497m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tramadol hydrochloride NPV Report.

Tramadol hydrochloride is currently owned by Grunenthal. Nippon Shinyaku is the other company associated in development or marketing of Tramadol hydrochloride.

Tramadol hydrochloride Overview

Tramadol hydrochloride (Tramal, Zydol, Tradonal, Adolonta, Contramal, Tradol) is a centrally acting synthetic opioid analgesic. It is formulated as hard gelatin capsules, tablets, suspension, soluble tablets, solution drops for oral route of administration and as solution, powder for solution for intramuscular or intravenous or subcutaneous administration, suppositories for rectal route of administration. Tramadol hydrochloride is indicated for the treatment of mild pain, moderate to severe pain, acute and chronic pain, cancer pain, traumatic pain and surgery pain.

Nippon Shinyaku Overview

Nippon Shinyaku develops, manufactures, and sells ethical pharmaceuticals and functional foods. The company offers a wide range of products including drugs for pain, inflammation, and allergies; urological diseases; hematologic malignancies; gastrointestinal disorders; cardiovascular and metabolic diseases among others. Nippon Shinyaku also provides functional food ingredients including health food ingredients, preservatives, spices and condiments, and protein preparations. Its functional food products find application in meat processing, fish processing, dairy product, prepared food, confectionery and bakery, and beverage, among others. The company operates business through a network of offices and research laboratories located in Japan, China, the UK and the US. Nippon Shinyaku is headquartered in Minami-ku, Kyoto, Japan.

The company reported revenues of (Yen) JPY137,484 million for the fiscal year ended March 2022 (FY2022), an increase of 12.8% over FY2021. In FY2022, the company’s operating margin was 20.6%, compared to an operating margin of 21.4% in FY2021. In FY2022, the company recorded a net margin of 16.8%, compared to a net margin of 17% in FY2021. The company reported revenues of JPY35,517 million for the second quarter ended September 2022, a decrease of 0.3% over the previous quarter.

Quick View – Tramadol hydrochloride

Report Segments
  • Innovator (NME)
Drug Name
  • Tramadol hydrochloride
Administration Pathway
  • Intramuscular
  • Intravenous
  • Oral
  • Rectal
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.